Dr. Tse-Wen Chang, Chairman
Please see Founder.
Mr. Jung-Chin Lin, Director
He has over the last 20 years transformed the Center Laboratories Inc. into a biotech and pharmaceutical investment house with a diverse portfolio, including Mycenax Biotech, Lumosa Therapeutics, Adimmune Corp., TOT Biopharma, Jacobio Pharmaceutical Group, and many others.
Mr. Lin serves as a chairman, director, advisor in many of his portfolio companies. He values innovative technologies and envisions antibody drug conjugates, cell therapy, and genetic therapy to play import roles in pharmaceutical industry.
Mr. Lin received B.Sc. degree in pharmacy from Taipei Medical University and was recognized with an honorary doctorate degree by the same university.
Mr. Shang-Hung Shen, Director
Mr. Shen is serving as the Chairman of TA YA Electrical Wire and Cable Co., a reputable, very established company in the field. He is also serving as the Chairman of TA YA Venture Capital Co. Before assuming the Chairmanship in TA YA, he worked as a manager in AT&T.
TA YA Venture placed all investments in communication industry and green energy in earlier periods, but has shifted half of the capital to biotech and pharmaceutical industry in recent years. Mr. Shen emphasizes nurturing corporate culture and employees’ health/welfare and education.
He received B.Sc. in Electrical Engineering from National Taiwan University and MBA from Emory University.
Ms. Audrey Tseng, Director
Ms. Tseng is an Honorary Deputy Chairman of PwC Taiwan, a member of BioTaiwan Committee, an advisor to BioTReC of Academia Sinica, and an advisor to Ministry of Health and Welfare.
With over 35 years of experience as a Taiwan-licensed CPA, she has assisted numerous biopharma and medtech companies in financial management and public listing in Taiwan. She has also served advisory roles for some of these companies to go IPO in overseas markets.
Ms. Tseng received an MBA from the joint Executive Program of Fudan University and National Taiwan University, and a Master of Commerce from National Chengchi University.
Mr. James C. Ho, Director
Mr. Ho is serving as the Chairman of CDIB Capital Management Co. and has ~30 years of experience in industrial policy, investment practices, and corporate operations. He has served as the chairman of PharmaEngine, Inc., as well as the supervisor or director of several companies, such as CDIB, Andes Technology Co. and TSMC, actively promoting the development of private equity funds in the healthcare field.
While serving as the deputy executive secretary of the National Development Fund, he was committed to promoting investment in Taiwanese and overseas venture capital companies, making national strategic industry investments, and was responsible for evaluating and investing in many Taiwanese biotechnology innovations and strategic companies. He was instrumental in aiding over 80% of these companies in successfully completing their listings.
Mr. Ho received his master’s/doctoral degree in economics from the University of Pittsburgh, Pennsylvania.